Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors

     Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors

PR Newswire

PITTSBURGH, Feb. 11, 2013

PITTSBURGH, Feb. 11, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its board of directors has voted unanimously to appoint Melina
Higgins, a former partner at Goldman, Sachs & Co., and Rajiv Malik, currently
Mylan's president, to Mylan's board. With the appointments of Higgins and
Malik, Mylan has expanded its board to 13 members.

Melina Higgins is an experienced financier, having served as a partner and in
other senior roles at Goldman Sachs during her nearly 20 year career at the
firm. Higgins joined Goldman Sachs in 1989 and retired from the firm in
January 2010.During her tenure at Goldman Sachs, Higgins served as a member
of the Investment Committee of the Principal Investment Area, which oversaw
and approved global private equity and private debt investments and was one of
the largest alternative asset managers in the world. She also served as head
of the Americas as well as co-chairperson of the Investment Advisory Committee
for the GS Mezzanine Partners funds, which managed over $30 billion of assets
and was the global leader in its industry.

Higgins has significant board experience, having served as a director for
numerous companies across a wide range of industries.U.S. Banker ranked
Higgins as one of the Top 20 Nonbank Women in Finance.She holds an M.B.A.
from Harvard Business School and a B.A. from Colgate University.

Higgins said, "I believe Mylan is truly differentiated within the industry and
very well-positioned to continue to generate value for its shareholders by
executing on its strategy. I am very excited to be joining Mylan's board and
look forward to working alongside my fellow directors and Mylan's highly
talented management team during this period of continued anticipated growth
and strategic evolution for the company."

Mylan Executive Chairman Robert J. Coury commented: "With these appointments,
I am very pleased to continue to deliver on our objective of enhancing and
strengthening Mylan at all levels, including its board of directors, as we
seek to continue our exciting growth trajectory. Our entire board and I have
been extremely impressed with Melina's deep knowledge of, and experience in,
the financial markets, understanding of optimal corporate structures and track
record of unleashing shareholder value during her career in private equity.
Melina also brings Mylan deep market insights and relationships across the
financial community. I am pleased to welcome Melina to the Mylan board of
directors and look forward to benefiting from her contributions to the

Rajiv Malik is currently Mylan's president, responsible for the company's
operations, including oversight for research and development, business
development, regulatory affairs, manufacturing operations and strategy,
quality, supply chain, sourcing, packaging and medical affairs, as well as the
sales and marketing of Mylan's generics business. Malik has held important
leadership positions at Mylan since January 2007, when the company acquired a
controlling stake in Matrix Laboratories Limited (now Mylan Laboratories
Limited), one of the world's largest suppliers of active pharmaceutical
ingredients. At the time of the acquisition, Malik was Matrix's chief
executive officer.

During his tenure at Mylan, Malik has played a key role in significantly
expanding and diversifying Mylan's global product portfolio, pipeline and
manufacturing footprint. In partnership with Mylan's leadership team, Malik
played a significant role in leading the integrations of Mylan and Matrix and
Mylan and the generics business of Merck KGaA to leverage the benefits of
global scale and vertical and horizontal integration. Malik also is
responsible for helping lead Mylan's expansion into emerging and other new
commercial markets, such as the company's recent commercial launch in India,
and he has helped establish Mylan as a leader in antiretroviral (ARV)
medicines, particularly in developing markets.

Malik has approximately 30 years of experience in the global generic
pharmaceutical industry. Prior to joining Matrix in 2005, Malik was head of
Global Development and Regulatory at Sandoz. He started his R&D career at
Ranbaxy Laboratories, rising to head of Generics R&D. Malik earned his
master's degree in pharmaceutical technology from Punjab University, India,
and has more than 60 process patents to his credit.

"I feel privileged and honored to be elevated to the Mylan board. Since
joining Mylan following the acquisition of Matrix, I have felt like a part of
the Mylan family, a feeling shared by many others who have joined me on this
exciting journey over the past few years," said Malik. "I have had the
opportunity to work closely with our passionate leadership team and talented
people across the Mylan organization to build a strong foundation and help
transform Mylan into a powerful global force in our industry. I am very
excited about our very promising future and look forward to adding further
value to my fellow board members, as well as the rest of the leadership team,
in accomplishing Mylan's mission and achieving its strategic and financial

Coury commented: "Rajiv has made extraordinary contributions throughout his
tenure at Mylan. He has helped generate meaningful value for our shareholders
through his strong leadership and impressive operational and technical
prowess, played an instrumental role in executing against Mylan's strategic
growth drivers, and demonstrated unwavering commitment to Mylan and its
mission. In addition to his deep knowledge of Mylan's business, Rajiv brings
tremendous knowledge of the Asia-Pacific region to the board. I and Mylan's
other directors are thrilled to welcome Rajiv to the board of directors and
look forward to his continued contributions to Mylan at this level."

This press release includes statements that constitute "forward-looking
statements," including with regard to the company's future growth and
performance. These statements are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Because such
statements inherently involve risks and uncertainties, actual future results
may differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause or contribute to such differences
include, but are not limited to: the impacts of competition; changes in
economic and financial conditions of the company's business; uncertainties and
matters beyond the control of management; and the other risks detailed in the
company's filings with the Securities and Exchange Commission. The company
undertakes no obligation to update these statements for revisions or changes
after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit, do what's right, not what's easy
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately one-third of HIV/AIDS patients in developing
countries depend. We also operate one of the largest active pharmaceutical
ingredient manufacturers and currently market products in approximately 150
countries and territories. Our workforce of more than 18,000 people is
dedicated to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for it. See for
yourself. See inside.

SOURCE Mylan Inc.

Contact: Nina Devlin (Media), 724.514.1968, or Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.